Meanings of lymphoblastic leukaemia in English

The five-year-old has T-cell acute lymphoblastic leukaemia, which is particularly aggressive and progresses quickly.

Continuation chemotherapy is a key component of the treatment of childhood acute lymphoblastic leukaemia.

We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens.

Together, these findings suggest that there is no stem cell hierarchy in acute B lymphoblastic leukaemia.

Background: The addition of rituximab to intensive chemotherapy improves outcomes in patients with B-cell acute lymphoblastic leukaemia.

Balance abilities have been investigated solely in survivors of acute lymphoblastic leukaemia or central nervous system tumours.

The least number of relapses was recorded in the investigation period in children with hyperploid acute lymphoblastic leukaemia.

Background: Prognosis of patients with relapsed or refractory acute lymphoblastic leukaemia is poor and new treatments are needed.

The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown.

TEL-AML1 gene fusion due to chromosomal translocation is frequently seen in the common form of childhood acute lymphoblastic leukaemia.

We therefore studied the activity of TRAIL in 29 primary precursor B-cell acute lymphoblastic leukaemia (ALL) samples.

Background: Combination of chemotherapy with a tyrosine-kinase inhibitor is effective in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Interpretation: Our findings showed that childhood acute lymphoblastic leukaemia is frequently initiated by a chromosome translocation event in utero.

To demonstrate accuracy in a biological setting, we apply the method to monitor minimal residual disease in acute lymphoblastic leukaemia patients.

Conclusion: A more intensive delayed consolidation phase improved the outcome for children with acute lymphoblastic leukaemia by reducing relapses at 4 years.

Objective: To study the outcome of children with acute lymphoblastic leukaemia who were treated using a protocol including one or two delayed intensifications.